40
Participants
Start Date
July 31, 2024
Primary Completion Date
January 31, 2026
Study Completion Date
July 31, 2026
QTORIN 3.9% Rapamycin Anhydrous Gel
QTORIN 3.9% Rapamycin Anhydrous Gel
RECRUITING
Vascular Birthmark Institute, New York
RECRUITING
Penn State Hershey Medical Center, Hershey
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
University of North Carolina, Chapel Hill
RECRUITING
Children's Healthcare of Atlanta, Atlanta
RECRUITING
Vanderbilt Children's Hospital, Nashville
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Cincinnati Children's Hospital, Cincinnati
RECRUITING
Minnesota Clinical Study Center, New Brighton
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Texas Children's Hospital, Houston
NOT_YET_RECRUITING
University of Texas, Dell Children's, Austin
RECRUITING
University of Utah Health, Salt Lake City
RECRUITING
Children's Hospital of Orange County, Irvine
RECRUITING
Stanford University, Palo Alto
Lead Sponsor
FDA Office of Orphan Products Development
FED
Palvella Therapeutics, Inc.
INDUSTRY